NSAIDs increase survival in the Sandhoff disease mouse: Synergy with N‐butyldeoxynojirimycin
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The GM2 gangliosidoses are caused by incomplete catabolism of GM2 ganglioside in the lysosome, leading to progressive storage and a neurodegenerative clinical course. An inflammatory response (microglial activation, macrophage infiltration, oxidative damage) has been found to be a consequence of GM2 storage in the brain, although it remains unclear whether this contributes to pathogenesis or disease progression. In this study, we treated Sandhoff disease mice with nonsteroidal antiinflammatory drugs (indomethacin, aspirin, and ibuprofen) and antioxidants (L‐ascorbic acid and α‐tochopherol acetate). The treated mice lived significantly longer than untreated littermates (12–23%, p < 0.0001) and showed a slower rate of disease progression (p < 0.001). When aspirin treatment was combined with substrate reduction therapy, synergy resulted (11%, p < 0.05) with a maximum improvement of 73% in survival (p < 0.00001). This study demonstrates that inflammation contributes to disease progression and identifies antiinflammatory and antioxidant therapies as a potential adjunctive approach to slow the clinical course of this and related disorders. Ann Neurol 2004;56:642–649
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sango, K., Yamanaka, S., Hoffmann, A., Okuda, Y., Grinberg, A., Westphal, H., McDonald, M. P., Crawley, J. N., Sandhoff, K., Suzuki, K., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-170 · Cited by 468 · cited 1×
“Sandhoff disease mice were obtained from Richard Proia (National Institutes of Health, Bethesda, MD).(9) All mice”
MethodThe impact of systemic infection on the progression of neurodegenerative disease
Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428 · cited 1×
“Activation of the innate immune system may have different consequences at different stages in disease progression, perhaps initially being protective but later exacerbating disease.(16,17) The outcome of pharmacologically targeting inflammation is therefore impossible to predict and must be determined empirically.”
Background
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Self-citationNeufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases
Vitner, E. B., Platt, F. M., & Futerman, A. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.134452 · Cited by 369
Self-citationSphingolipid metabolism diseases
Kolter, T., & Sandhoff, K. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.05.027 · Cited by 367
Sphingolipid lysosomal storage disorders
Platt, F. M. (2014) · Nature · doi:10.1038/nature13476 · Cited by 320
Self-citation
Metadata
- Authors
- Jeyakumar, M., Smith, D. A., Williams, I. M., Borja, M. C., Neville, D. C. A., Butters, T. D., Dwek, R. A., & Platt, F. M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-10-25
- Volume
- 56
- Issue
- 5
- Pages
- 642-649
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2029965274
- Cited by
- 118
- References
- 2
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.